nach oben

Erschienen in:

08.08.2023 | Review

Incretins beyond type 2 diabetes

verfasst von: Chantal Mathieu, Iraj Ahmadzai

Erschienen in: Diabetologia | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Incretin-based therapies, in particular glucagon-like peptide-1 (GLP-1) receptor agonists, have been evaluated in other forms of diabetes, but randomised controlled trials are mainly limited to people living with type 1 diabetes. In this review we present the evidence issuing from these trials and discuss their clinical implications as well as the difficulties in interpreting the data. In type 1 diabetes, the addition of GLP-1 receptor agonists to intensive insulin therapy lowers weight and required insulin doses compared with placebo, but the effects on glucose control (HbA_1c, risk of hypoglycaemia) are dependent on the different study protocols. Side effects are limited to the gastrointestinal complaints of nausea, vomiting and diarrhoea. We briefly discuss the potential for using GLP-1 receptor agonists as (adjunct) therapies in other forms of diabetes, where the evidence to date is scarce.

Graphical Abstract

Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925–1966. https://doi.org/10.1007/s00125-022-05787-2CrossRefPubMedPubMedCentral

Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740–756. https://doi.org/10.1016/j.cmet.2018.03.001CrossRefPubMed

Holt RIG, DeVries JH, Hess-Fischl A et al (2021) The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 64(12):2609–2652. https://doi.org/10.1007/s00125-021-05568-3CrossRefPubMedPubMedCentral

Gregory GA, Robinson TIG, Linklater SE et al (2022) Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol 10(10):741–760. https://doi.org/10.1016/S2213-8587(22)00218-2CrossRefPubMed

Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C (2021) Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol 9(11):776–785. https://doi.org/10.1016/S2213-8587(21)00246-1CrossRefPubMed

Taylor SI, Blau JE, Rother KI, Beitelshees AL (2019) SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol 7(12):949–958. https://doi.org/10.1016/S2213-8587(19)30154-8CrossRefPubMedPubMedCentral

Timmons JG, Littlejohn L, Boyle JG, Petrie JR (2022) Recent developments in adjunct therapies for type 1 diabetes. Expert Opin Investig Drugs 31(12):1311–1320. https://doi.org/10.1080/13543784.2022.2159806CrossRefPubMed

Petrie JR, Chaturvedi N, Ford I et al (2017) Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5(8):597–609. https://doi.org/10.1016/S2213-8587(17)30194-8CrossRefPubMedPubMedCentral

Janssens B, Caerels S, Mathieu C (2020) SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects. Ther Adv Endocrinol Metab 11:204201882093854. https://doi.org/10.1177/2042018820938545CrossRef

10.

Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors. Diabetes Care 42(6):1147–1154. https://doi.org/10.2337/dc18-2316CrossRefPubMedPubMedCentral

11.

Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C (2022) Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: a European two-center experience. Diabetes Care 45(3):650–658. https://doi.org/10.2337/dc21-1584CrossRefPubMed

12.

Müller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72–130. https://doi.org/10.1016/j.molmet.2019.09.010CrossRefPubMedPubMedCentral

13.

Hammoud R, Drucker DJ (2023) Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 19(4):201–216. https://doi.org/10.1038/s41574-022-00783-3CrossRefPubMed

14.

Brock C, Hansen CS, Karmisholt J et al (2019) Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. Br J Clin Pharmacol 85(11):2512–2523. https://doi.org/10.1111/bcp.14063CrossRefPubMedPubMedCentral

15.

Frandsen CS, Dejgaard TF, Andersen HU et al (2017) Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo-controlled, double-blind, parallel-group study. Diabetes Obes Metab 19(6):773–782. https://doi.org/10.1111/dom.12830CrossRefPubMed

16.

Schmidt S, Frandsen CS, Dejgaard TF et al (2022) Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes. Diabetes Obes Metab 24(2):212–220. https://doi.org/10.1111/dom.14567CrossRefPubMed

17.

Wegeberg A, Meldgaard T, Bæk A et al (2021) Subcutaneous adipose tissue composition and function are unaffected by liraglutide-induced weight loss in adults with type 1 diabetes. Basic Clin Pharmacol Toxicol 128(6):773–782. https://doi.org/10.1111/bcpt.13575CrossRefPubMedPubMedCentral

18.

Jiang L-L, Wang S-Q, Ding B et al (2018) The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus. J Endocrinol Invest 41(5):539–547. https://doi.org/10.1007/s40618-017-0765-0CrossRefPubMed

19.

Ahrén B, Hirsch IB, Pieber TR et al (2016) Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 39(10):1693–1701. https://doi.org/10.2337/dc16-0690CrossRefPubMed

20.

Dejgaard TF, Schmidt S, Frandsen CS et al (2020) Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial—a randomized, double-blinded, placebo-controlled trial. Diabetes Obes Metab 22(4):492–500. https://doi.org/10.1111/dom.13911CrossRefPubMed

21.

Dejgaard TF, Frandsen CS, Hansen TS et al (2016) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 4(3):221–232. https://doi.org/10.1016/S2213-8587(15)00436-2CrossRefPubMed

22.

Dubé M, D’Amours M, Weisnagel SJ (2018) Beyond glycaemic control: a cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. Diabetes Obes Metab 20(1):178–184. https://doi.org/10.1111/dom.13063CrossRefPubMed

23.

Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S (2015) Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care 38(12):2250–2257. https://doi.org/10.2337/dc15-1037CrossRefPubMed

24.

Ghanim H, Batra M, Green K et al (2020) Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab 22(10):1742–1752. https://doi.org/10.1111/dom.14090CrossRefPubMed

25.

Kuhadiya ND, Dhindsa S, Ghanim H et al (2016) Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care 39(6):1027–1035. https://doi.org/10.2337/dc15-1136CrossRefPubMedPubMedCentral

26.

Mathieu C, Zinman B, Hemmingsson JU et al (2016) Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39(10):1702–1710. https://doi.org/10.2337/dc16-0691CrossRefPubMed

27.

Herold KC, Reynolds J, Dziura J et al (2020) Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obes Metab 22(11):2045–2054. https://doi.org/10.1111/dom.14121CrossRefPubMedPubMedCentral

28.

Johansen NJ, Dejgaard TF, Lund A et al (2020) Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 8(4):313–324. https://doi.org/10.1016/S2213-8587(20)30030-9CrossRefPubMed

29.

Østoft SH, Bagger JI, Hansen T et al (2014) Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care 37(7):1797–1805. https://doi.org/10.2337/dc13-3007CrossRefPubMed

30.

von Herrath M, Bain SC, Bode B et al (2021) Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 9(4):212–224. https://doi.org/10.1016/S2213-8587(21)00019-XCrossRef

31.

Seaquist ER, Teff K, Heller SR (2022) Impaired awareness of hypoglycemia in type 1 diabetes: a report of an NIDDK workshop in October 2021. Diabetes Care 45(12):2799–2805. https://doi.org/10.2337/dc22-1242CrossRefPubMed

32.

Dejgaard TF, von Scholten BJ, Christiansen E et al (2021) Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes Metab 23(12):2752–2762. https://doi.org/10.1111/dom.14532CrossRefPubMedPubMedCentral

33.

Rondas D, Bugliani M, D’Hertog W et al (2013) Glucagon-like peptide-1 protects human islets against cytokine-mediated β-cell dysfunction and death: a proteomic study of the pathways involved. J Proteome Res 12(9):4193–4206. https://doi.org/10.1021/pr400527qCrossRefPubMed

34.

Kero J, Koskenniemi JJ, Karsikas S et al (2022) INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 DIAbetes in autoantibody positive participants: a protocol for three parallel double‐blind, randomised controlled trials (INVESTDIA). Diabetic Med 39(10):e14913. https://doi.org/10.1111/dme.14913CrossRefPubMed

35.

Ballav C, Dhere A, Kennedy I et al (2020) Lixisenatide in type 1 diabetes: a randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinol Diabetes Metab 3(3):e00130. https://doi.org/10.1002/edm2.130CrossRefPubMedPubMedCentral

36.

Singh AK, Gangopadhyay KK, Singh R (2020) Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Rev Clin Pharmacol 13(4):461–468. https://doi.org/10.1080/17512433.2020.1736041CrossRefPubMed

37.

Lawrence SE, Chandran MM, Park JM et al (2023) Sweet and simple as syrup: a review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation. Clin Transplant 37(3):e14922. https://doi.org/10.1111/ctr.14922CrossRefPubMed

38.

van Raalte DH, van Genugten RE, Linssen MML, Ouwens DM, Diamant M (2011) Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34(2):412–417. https://doi.org/10.2337/dc10-1677CrossRefPubMedPubMedCentral

39.

Uchinuma H, Ichijo M, Harima N, Tsuchiya K (2020) Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin. BMC Endocr Disord 20(1):58. https://doi.org/10.1186/s12902-020-0542-5CrossRefPubMedPubMedCentral

40.

Elkind-Hirsch KE, Shaler D, Harris R (2020) Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: a double-blind, randomized, placebo-controlled study. J Diabetes Complications 34(4):107548. https://doi.org/10.1016/j.jdiacomp.2020.107548CrossRefPubMed

Titel: Incretins beyond type 2 diabetes
verfasst von: Chantal Mathieu
Iraj Ahmadzai
Publikationsdatum: 08.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 10/2023
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-023-05980-x

Up Front

Up Front

Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial

Open Access
Article

Strength training is more effective than aerobic exercise for improving glycaemic control and body composition in people with normal-weight type 2 diabetes: a randomised controlled trial

Article

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Open Access
Review

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study

Open Access
Article

Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study

Short Communication

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

"Die Erektionsstörung ist keine isolierte Erkrankung"

21.01.2025
Erektile Dysfunktion
Podcast

Werden Erektionsstörungen gut behandelt (und das ist möglich), steigt die Lebensqualität enorm. Tipps für eine gute Kommunikation mit den Patienten gibt Androloge Dr. med. Jann-Frederik Cremers in dieser Folge. Welche Fragen sollten gestellt und an welche Ursachen gedacht werden? Und was ist zu tun, wenn PDE-5-Hemmer und Lebensstilveränderungen nicht ausreichend wirken?

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

20.01.2025
Koronare Herzerkrankung
Nachrichten

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

20.01.2025
Chronische Herzinsuffizienz
Nachrichten

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Incretins beyond type 2 diabetes

Abstract

Graphical Abstract

Weitere Artikel der Ausgabe 10/2023

Up Front

Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial

Strength training is more effective than aerobic exercise for improving glycaemic control and body composition in people with normal-weight type 2 diabetes: a randomised controlled trial

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study

Glycaemic control, risk of hypoglycaemia and all-cause mortality in new users of second-generation basal insulin with type 2 diabetes and chronic kidney disease: a nationwide register-based cohort study

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Neu im Fachgebiet Innere Medizin

"Die Erektionsstörung ist keine isolierte Erkrankung"

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

Update Innere Medizin

Springer Medizin

Abstract

Graphical Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten